Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells

Prostate

Volumn 52, Issue 1, 2002, Pages 20-33

  Corey, Eva ^a   Quinn, Janna E ^a   Bladou, Franck ^b   Brown, Lisha G ^a   Roudier, Martine P ^a   Brown, Julie M ^a   Buhler, Kent R ^a   Vessella, Robert L ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Animal model; Bone metastasis; Osteoblastic response; Osteolytic response; Prostate cancer

Indexed keywords

ENDOTHELIN 1; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE GROWTH; BONE METASTASIS; BONE RADIOGRAPHY; BONE REMODELING; CANCER CELL; CANCER MODEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; TIBIA;

ANIMALS; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; PROSTATIC NEOPLASMS; PROTEINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TIBIA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036604237     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10091     Document Type: Article

References (47)

1. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer
2. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
3. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases
4. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved
5. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: Examination with bone X-ray
6. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption
7. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia
8. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer
9. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastic bone disease
10. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer
11. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
12. Development of skeletal metastasis by human prostate cancer in athymic nude mice
13. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice
14. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
15. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
16. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines
17. WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma
18. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone
19. The function of the vertebral veins and their role in the spread of metastasis
20. The distribution of secondary growths in cancer of the breast
21. Experimental approaches to skeletal metastasis of human prostate cancer
22. Advanced prostate cancer follow-up with prostate specific antigen, prostatic acid phosphatase, osteocalcin, and bone isoenzyme of alkaline phosphatase
23. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer
24. Detection of occult prostate cancer in achieved pelvic lymph nodes by PSA- and prostate-specific membrane (PSM) Antigen-RT-PCR
25. Osteopontin expression and distribution in human carcinomas
26. Carboxyl-terminal parathyroid hormone-related protein inhibits bone resorption by isolated chicken osteoclasts
27. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SAOS-4/3 cells expressing recombinant PTH/PTHrP receptors
28. Molecular control of bone remodeling and osteoporosis
29. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
30. Osteoprotegerin and osteoclast differentiation factor expression in prostate cancer
31. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer
32. LNCaP model of human prostatic carcinoma
33. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
34. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.1
35. LuCaP 35: An androgen inducible, prostate-specific antigen producing human prostate cancer xenograft
36. Study of free and complexed prostate-specific antigen in mice bearing human prostate cancer xenografts
37. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice
38. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice
39. Histochemistry and immunohistochemistry on bone marrow biopsies. A rapid procedure for methyl methacrylate embedding
40. Modifications of the Goldner and Gomori one-step trichrome stains for plastic-embedded thin sections of bone
41. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells
42. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts
43. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts
44. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen
45. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
46. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth
47. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism